IL13RA2-integrated genetically engineered mouse model allows for CAR T cells targeting pediatric high-grade gliomas

Area of Science:

• Neuro-oncology
• Immunotherapy
• Genetically Engineered Mouse Models

Background:

• Pediatric high-grade gliomas (pHGG) and diffuse midline gliomas (pDMG) lack effective treatments.
• Targeted immunotherapies show promise but require suitable preclinical models.
• Existing models often lack a fully functional immune system for studying immunotherapy.

Purpose of the Study:

• To develop a fully immunocompetent, genetically engineered mouse model (GEMM) for pDMG and pHGG.
• To incorporate the glioma-associated antigen, interleukin 13 receptor alpha 2 (IL13RA2), for targeted therapy evaluation.
• To assess the efficacy of IL13RA2-targeted immunotherapy in this novel preclinical model.

Main Methods:

• Utilized the RCAS-Tva system in Nestin-Tva mice for gliomagenesis.
• Induced tumors by overexpressing PDGFB and deleting p53 or both p53 and PTEN.
• Incorporated IL13RA2 expression in some models for targeted therapy studies.

Main Results:

• Developed de novo pDMG/pHGG models with or without IL13RA2, exhibiting aggressive glioma features.
• Observed no significant difference in tumor onset between models with or without IL13RA2.
• Demonstrated significant survival extension (p < 0.0001) and 25% long-term survival with CAR T-cell therapy targeting IL13RA2.

Conclusions:

• The developed GEMM is a valuable tool for preclinical evaluation of IL13RA2-targeted therapies for pediatric gliomas.
• This model recapitulates key features of human gliomas and the tumor microenvironment.
• The findings support the potential clinical application of IL13RA2-directed immunotherapies in pediatric glioma patients.